BUY Axis Bank

Growth, asset quality slip, but valuations comforting

BFSI - Banks > Result Update > January 17, 2025

Axis Bank continues to report weak credit growth, which has now slipped to 9% YoY; this, along with margin contraction (of 6bps QoQ) and higher retail slippages (net at Rs29bn vs Rs22bn in 2Q) led to elevated provisions. However, operational cost too is on the decline QoQ, containing the earnings miss at 4% to Rs63bn/RoA@1.7%. Credit growth moderation was mainly driven by slowdown in the bank's retail book (incl unsecured loans and corporate book), which is likely to stay soft amid liquidity and asset quality challenges. The mgmt believes unsecured loan stress will remain elevated near term, but seasonal stress in the agri portfolio should ease QoQ. Building in the slower credit growth and higher LLP, partly offset by moderating opex, we cut earnings by 3-9% over FY25-27E. The stock has seen sharp correction recently and trades at relatively lower valuations of 1.3x Dec-26E ABV for a bank still delivering healthy 1.7% RoA/14-16% RoE. Thus, we retain BUY, and cut our TP to Rs1,300 (from Rs1,400), valuing the SA bank at 1.7x Dec-26E ABV and subs at Rs110/sh.

Axis Bank: Financial	Snapshot (Standalon	e)		
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net profit	95,797	248,614	259,420	279,019	318,480
Loan growth (%)	19.4	14.2	7.5	9.8	14.0
NII growth (%)	29.6	16.2	8.9	5.2	10.7
NIM (%)	3.7	3.8	3.8	3.7	3.7
PPOP growth (%)	30.5	15.0	13.6	7.3	13.7
Adj. EPS (INR)	31.2	80.5	83.8	90.1	102.9
Adj. EPS growth (%)	-26.6	159.0	4.1	7.6	14.1
Adj. BV (INR)	390.7	472.1	555.9	642.0	740.6
Adj. BVPS growth (%)	10.2	20.8	17.8	15.5	15.4
RoA (%)	0.8	1.8	1.7	1.7	1.7
RoE (%)	8.0	18.0	15.8	14.6	14.4
P/E (x)	13.0	11.5	11.1	10.3	9.0
P/ABV (x)	2.3	1.9	1.6	1.4	1.2

Source: Company, Emkay Research

Credit growth, margin slip further

Axis Bank continues to report sluggish growth, well below the system's, at 9% YoY/1.5% QoQ, due to a marked slowdown in its retail book, including unsecured loans and corporate book. However, SME book growth remains relatively higher at 15% YoY. Deposits growth too moderated further to 9% YoY/1% QoQ, with LDR at around 92.6% and CASA cannibalization continues, leading to fall in CASA ratio to 39.5%. NIM too slipped, by 6bps QoQ to 3.93%, including 3bps QoQ contribution from interest reversal on NPAs and 3bps due to higher LCR (up by 400bps QoQ to 119%). Axis Bank believes FY25 credit growth will be anchored by deposit growth/LDR, which is still a challenge. Thus, we cut our FY25 credit growth estimates further, to 7% from 12% earlier.

Slippages inch-up, but higher write-offs contain the NPAs

Gross slippages inched up QoQ to Rs54bn/2.3% of loans, while the bank continued to pursue an aggressive write-off policy leading to slight increase in GNPA ratio to 1.46%. Though corporate net slippages remain in the negative zone, retail net slippages inched up QoQ to Rs29bn vs Rs22bn in 2Q, which could be partly due to seasonally higher agri slippages and continued elevated unsecured retail slippages, including Cards, PL, and MFI loans. The bank's specific PCR has moderated further to 76%, but the bank carries contingent provision buffer of Rs50bn/0.55% of loans. The bank claims that its CET 1 ratio (14.6%), including the contingent provision buffer, would be comfortable at 15%.

We retain BUY, and trim our TP to Rs1,300

Factoring in the slower credit growth and higher LLP, partly offset by moderating operational cost, we trim our earnings estimates by 3-9% over FY25-27. However, we retain BUY and cut our TP to Rs1,300 (from Rs1,400 earlier), now valuing the standalone bank at 1.7x Dec-26E ABV and subsidiaries at Rs110 per share. **Key risks:** Macrodislocation and more than expected stress in unsecured loans leading to slower-than-expected growth/higher NPAs, and KMP attrition.



TARGET PRICE (Rs): 1,300

Target Price – 12M	Dec-25
Change in TP (%)	(7.1)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	25.2
CMP (16-Jan-25) (Rs)	1,038.0
Stock Data	Ticker
52-week High (Rs)	1,340
52-week Low (Rs)	996
Shares outstanding (mn)	3,095.3
Market-cap (Rs bn)	3,213
Market-cap (USD mn)	37,122
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	8
ADTV-3M (Rs mn)	9,478.8
ADTV-3M (USD mn)	109.5
Free float (%)	90.0
Nifty-50	23,312
INR/USD	86.6
Shareholding, Dec-24	
Promoters (%)	7.9
FPIs/MFs (%)	45.5/36.0

Price Performance						
(%)	1M	3M	12M			
Absolute	(9.8)	(10.0)	(7.2)			
Rel. to Nifty	(4.6)	(3.6)	(12.3)			



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Nikhil Vaishnav

nikhil.vaishnav@emkayglobal.com +91 22 6624 2485

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions Refer to Important Disclosures at the end of this report and end of this report on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Growth slips below the system level...



Source: Company, Emkay Research

Exhibit 3: CASA ratio slips below 40% due to cannibalization...



Source: Company, Emkay Research

Exhibit 5: Slippages remained elevated due to seasonal stress in agri and unsecured retail loans




Source: Company, Emkay Research

Exhibit 7: Net slippages are largely attributable to the higher net retail slippages




Source: Company, Emkay Research

Exhibit 2: ...mainly due to slower growth in the retail and corporate book




Source: Company, Emkay Research

Exhibit 4: ...which, coupled with interest reversal on NPAs and LCR impact, led to slight contraction in NIMs




Source: Company, Emkay Research

Exhibit 6: ...which, coupled with lower recoveries, led to higher net slippages



Source: Company, Emkay Research


Exhibit 8: GNPA ratio remained largely range-bound, but lower PCR led to uptick in NNPA ratio to 0.4%





Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research at 02 analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.










Source: Company, Emkay Research

Exhibit 11: Axis Bank continues to trade at lower valuations



Source: Bloomberg, Emkay Research

Exhibit 12: Actuals vs Estimates (Q3FY25)

(Rs mn)	Actuals	Estimates Variation		riation	Comments		
(Kš IIII)	Actuals		Consensus	Emkay	Consensus		
Net income	195,781	202,926	200,392	-4%	-2%	Decline in NIM, coupled with lower other income, led to decline in net income	
PPOP	105,339	105,552	103,744	0%	2%	Lower net income and improvement in opex led to a stable PPOP	
PAT	63,038	65,401	63,808	-4%	-1%	Stable PPOP and elevated provisions led to a miss on PAT	

Source: Company, Emkay Research

Exhibit 13: Quarterly Summary

(Rs mn)	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	YoY (%)	QoQ (%)	FY24A	FY25E	YoY (%)
Interest Earned	279,611	292,245	300,607	304,199	309,539	11	2	1,093,686	1,231,595	13
Interest Exp	154,290	161,355	166,125	169,367	173,481	12	2	594,741	688,147	16
Net Interest Income	125,322	130,890	134,482	134,832	136,059	9	1	498,945	543,448	9
Global NIMs (reported)	4.01	4.06	4.05	3.99	3.93	-8bps	-6bps	3.77	3.76	-2bps
Non-interest Income	55,548	67,658	57,835	67,219	59,722	8	-11	224,420	249,097	11
Operating Expenses	89,457	93,191	91,255	94,926	90,442	1	-5	352,132	370,799	5
Pre Provisioning Profit	91,412	105,357	101,062	107,125	105,339	15	-2	371,233	421,745	14
Provision & Contingencies	10,283	11,853	20,393	22,041	21,556	110	-2	40,631	83,432	105
PBT	81,129	93,504	80,669	85,084	83,782	3	-2	330,602	338,314	2
Income Tax Expense (Gain)	20,418	22,207	20,323	15,908	20,745	2	30	81,987	78,893	-4
Net Profit/(Loss)	60,711	71,297	60,346	69,176	63,038	4	-9	248,614	259,420	4
Gross NPA (%)	1.58	1.43	1.54	1.44	1.46	-12bps	2bps	1.47	1.52	5bps
Net NPA (%)	0.36	0.31	0.34	0.34	0.35	-1bps	1bps	0.34	0.38	5bps
Deposits (Rs bn)	10,049	10,686	10,625	10,867	10,959	9	1	10,686	11,343	6
Net Advances (Rs bn)	9,323	9,651	9,801	10,000	10,146	9	1	9,651	10,374	7

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY EGO> Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research ed at 02 analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 14: Revision in estimates

Y/E Mar (Rs mn)		FY25E			FY26E			FY27E	
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	813,856	792,544	-2.6%	916,156	857,799	-6.4%	1,065,467	964,431	-9.5%
РРОР	431,235	421,745	-2.2%	484,249	452,477	-6.6%	571,871	514,431	-10.0%
PAT	267,272	259,420	-2.9%	299,001	279,019	-6.7%	348,605	318,480	-8.6%
EPS (Rs)	86.4	83.8	-3.0%	96.7	90.1	-6.7%	112.7	102.9	-8.7%
BV (Rs)	578.2	575.3	-0.5%	673.1	663.7	-1.4%	783.4	764.2	-2.5%

Source: Company, Emkay Research

Exhibit 15: Key Assumptions									
(%)	FY24	FY25E	FY26E	FY27E					
Loan Growth	14.2	7.5	9.8	14.0					
Deposit Growth	12.9	6.1	10.6	15.1					
NIM	3.8	3.8	3.7	3.7					
GNPA	1.5	1.5	1.7	1.7					
Credit Cost	0.4	0.8	0.8	0.7					

Source: Emkay Research

Exhibit 16: Key Ratios and Trends

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	30FY25
Loans (Rs bn)	7,621	8,453	8,585	8,973	9,323	9,651	9,801	10,000	10,146
Growth YoY (%)	14.6	19.4	22.4	22.8	22.3	14.2	14.2	10,000	8.8
Composition (%)	14.0	19.4	22.7	22.0	22.5	17.2	17.2	11.4	0.0
- Corporate	32.9	31.4	31.8	31.4	30.6	28.7	29.7	29.1	29.0
- SME/BB	10.8	11.0	10.2	10.7	10.7	10.8	10.6	11.0	11.2
- Retail	56.3	57.7	58.0	57.9	58.7	60.4	59.7	59.9	59.7
Liability Profile (%)									
CASA	44.5	47.2	45.5	44.4	42.1	43.0	41.8	40.6	39.5
CA	14.9	15.7	14.2	13.8	13.2	14.7	14.1	13.1	13.1
SA	29.6	31.4	31.4	30.6	28.9	28.3	27.8	27.5	26.4
NIM (%)	4.3	4.2	4.1	4.1	4.0	4.1	4.1	4.0	3.9
NIM – Domestic (%)	4.4	4.4	4.2	4.2	4.1	4.2	4.1	4.1	4.1
Asset Quality									
GNPA (%)	2.6	2.2	2.1	1.8	1.7	1.5	1.6	1.5	1.5
NNPA (%)	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.4
PCR – Specific (%)	80.8	80.9	79.6	79.5	77.8	78.5	78.0	77.0	76.0
Slippages (Rs bn)	38.1	37.7	39.9	32.5	37.2	34.7	47.9	44.4	54.3
Slippages (%)	2.3	2.1	2.3	1.8	1.9	1.6	2.2	2.0	2.3
Capital Adequacy									
CAR (%)	19.5	17.6	17.7	17.8	16.6	16.6	16.7	16.6	17.0
Tier I (%)	16.2	14.6	14.9	15.1	14.2	14.2	14.1	14.5	15.0
ROE Decomposition (on total assets; %)									
NII	3.9	3.8	3.9	3.9	3.8	3.7	3.9	3.8	3.7
Other Income (Ex Treasury)	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.5
Treasury	0.1	0.0	0.2	(0.0)	0.1	0.3	0.1	0.3	0.1
Net income	5.5	5.3	5.6	5.5	5.5	5.7	5.6	5.7	5.4
Opex	2.3	2.4	2.7	2.8	2.7	2.7	2.6	2.7	2.5
РРОР	3.2	2.9	2.9	2.7	2.8	3.0	2.9	3.0	2.9
Provisions	0.5	0.1	0.3	0.3	0.3	0.3	0.6	0.6	0.6
РВТ	2.7	2.8	2.5	2.5	2.5	2.7	2.3	2.4	2.3
Tax	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.4	0.6
ROA	2.0	(1.8)	1.9	1.9	1.9	2.0	1.7	1.9	1.7
Leverage (x)	9.7	10.4	9.8	9.6	9.5	10.1	9.6	9.4	9.3
ROE	19.4	(19.0)	18.5	17.9	17.7	20.6	16.6	18.3	16.0
Source: Company, Emkay Bacaarch									

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research at 02 analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Axis Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY271
Interest Income	851,638	1,093,686	1,231,595	1,270,871	1,355,575
Interest Expense	422,180	594,741	688,147	699,015	722,299
Net interest income	429,457	498,945	543,448	571,856	633,27
NII growth (%)	29.6	16.2	8.9	5.2	10.
Other income	165,009	224,420	249,097	285,943	331,15
Total Income	594,466	723,365	792,544	857,799	964,43
Operating expenses	271,662	352,132	370,799	405,322	450,00
PPOP	322,805	371,233	421,745	452,477	514,43
PPOP growth (%)	30.5	15.0	13.6	7.3	13.
Core PPOP	325,555	353,272	401,957	428,731	488,31
Provisions & contingencies	28,848	40,631	83,432	80,903	88,11
РВТ	293,957	330,602	338,314	371,574	426,31
Extraordinary items	124,898	0	0	0	
Tax expense	73,262	81,987	78,893	92,555	107,83
Minority interest	0	0	0	0	
Income from JV/Associates	0	0	0	0	
Reported PAT	95,797	248,614	259,420	279,019	318,48
PAT growth (%)	69.4	12.7	4.3	7.6	14.
Adjusted PAT	220,695	248,614	259,420	279,019	318,48
Diluted EPS (INR)	31.1	80.5	83.8	90.1	102.9
Diluted EPS growth (%)	(-26.6)	159.0	4.0	7.6	14.
DPS (INR)	1.0	1.0	1.4	1.8	2.4
Dividend payout (%)	1.4	1.2	1.7	2.0	2.3
Effective tax rate (%)	24.9	24.8	23.3	24.9	25.
Net interest margins (%)	3.7	3.8	3.8	3.7	3.
Cost-income ratio (%)	45.7	48.7	46.8	47.3	46.
Shares outstanding (mn)	3,076.9	3,086.6	3,095.2	3,095.2	3,095.

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	6,154	6,173	6,190	6,190	6,190
Reserves & surplus	1,248,013	1,504,443	1,774,530	2,047,978	2,359,030
Net worth	1,254,167	1,510,616	1,780,720	2,054,168	2,365,220
Deposits	9,469,452	10,686,414	11,343,087	12,541,489	14,436,294
Borrowings	1,863,000	2,203,768	1,968,833	1,890,144	1,816,377
Interest bearing liab.	11,332,452	12,890,181	13.311.920	14,431,633	16,252,671
Other liabilities & prov.	586,636	371,289	512,000	572,568	727,328
Total liabilities & equity	13,173,255	14,772,086	15,604,641	17,058,369	19,345,220
Net advances	8,453,028	9,650,684	10,374,359	11,395,687	12,988,043
Investments	2,888,148	3,315,272	3,599,545	3,820,845	4,204,555
Cash, other balances	1,064,108	1,144,544	931,834	1,039,078	1,202,698
Interest earning assets	12,405,285	14,110,500	14,905,738	16,255,610	18,395,296
Fixed assets	47,339	56,846	102,662	114,332	127,367
Other assets					
	720,632	604,740	596,240	688,427	822,557
Total assets	720,632 13,173,255	,	596,240 15,604,641	688,427 17,058,369	822,557 19,345,22
Total assets BVPS (INR)	,			,	19,345,220
	13,173,255	14,772,086	15,604,641	17,058,369	19,345,220 754.4
BVPS (INR)	13,173,255 399.1	14,772,086 479.9	15,604,641 565.6 555.9	17,058,369 653.9 642.0	,
BVPS (INR) Adj. BVPS (INR)	13,173,255 399.1 390.7	14,772,086 479.9 472.1	15,604,641 565.6 555.9	17,058,369 653.9 642.0	19,345,220 754.4 740.6 13,159,204
BVPS (INR) Adj. BVPS (INR) Gross advances	13,173,255 399.1 390.7 8,588,828	14,772,086 479.9 472.1 9,761,659	15,604,641 565.6 555.9 10,493,783	17,058,369 653.9 642.0 11,543,162	19,345,220 754.4 740.6 13,159,204 90.0
BVPS (INR) Adj. BVPS (INR) Gross advances Credit to deposit (%)	13,173,255 399.1 390.7 8,588,828 89.3	14,772,086 479.9 472.1 9,761,659 90.3	15,604,641 565.6 555.9 10,493,783 91.5	17,058,369 653.9 642.0 11,543,162 90.9	19,345,220 754.4 740.6 13,159,204 90.0 40.7
BVPS (INR) Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%)	13,173,255 399.1 390.7 8,588,828 89.3 47.2	14,772,086 479.9 472.1 9,761,659 90.3 43.0	15,604,641 565.6 555.9 10,493,783 91.5 39.3	17,058,369 653.9 642.0 11,543,162 90.9 39.6	19,345,220 754.4 740.6
BVPS (INR) Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%)	13,173,255 399.1 390.7 8,588,828 89.3 47.2 3.6	14,772,086 479.9 472.1 9,761,659 90.3 43.0 4.5	15,604,641 565.6 555.9 10,493,783 91.5 39.3 5.2	17,058,369 653.9 642.0 11,543,162 90.9 39.6 5.0	19,345,220 754.4 740.6 13,159,204 90.0 40.7 4.6
BVPS (INR) Adj. BVPS (INR) Gross advances Credit to deposit (%) CASA ratio (%) Cost of deposits (%) Loans-to-Assets (%)	13,173,255 399.1 390.7 8,588,828 89.3 47.2 3.6 64.2	14,772,086 479.9 472.1 9,761,659 90.3 43.0 4.5 65.3	15,604,641 565.6 555.9 10,493,783 91.5 39.3 5.2 66.5	17,058,369 653.9 642.0 11,543,162 90.9 39.6 5.0 66.8	19,345,220 754.4 740.6 13,159,204 90.0 40.7 4.6 67.1

Source: Company, Emkay Research

Source: Company, Emkay Research

Asset quality and other metrics								
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E			
Asset quality								
Gross NPLs	170,190.2	143,449.7	159,232.4	196,632.2	228,214.3			
Net NPLs	34,390.4	32,474.7	39,808.1	49,158.0	57,053.6			
GNPA ratio (%)	2.0	1.5	1.5	1.7	1.7			
NNPA ratio (%)	0.4	0.3	0.4	0.4	0.4			
Provision coverage (%)	79.8	77.4	75.0	75.0	75.0			
Gross slippages	142,535.8	144,046.4	197,283.1	207,776.9	210,547.3			
Gross slippage ratio (%)	1.7	1.5	1.9	1.8	1.6			
LLP ratio (%)	0.4	0.4	0.8	0.8	0.7			
NNPA to networth (%)	2.6	2.1	2.1	2.3	2.3			
Capital adequacy								
Total CAR (%)	17.6	16.6	17.4	18.2	18.1			
Tier-1 (%)	14.6	14.2	15.5	16.4	16.4			
CET-1 (%)	14.1	14.1	15.4	16.3	16.4			
RWA-to-Total Assets (%)	68.3	74.0	74.0	75.2	77.6			
Miscellaneous								
Total income growth (%)	23.1	29.7	12.3	5.1	8.3			
Opex growth (%)	15.1	29.6	5.3	9.3	11.0			
Core PPOP growth (%)	39.3	8.5	13.8	6.7	13.9			
PPOP margin (%)	31.8	28.2	28.5	29.1	30.5			
PAT/PPOP (%)	68.4	67.0	61.5	61.7	61.9			
LLP-to-Core PPOP (%)	8.9	11.5	20.8	18.9	18.0			
Yield on advances (%)	8.4	9.7	9.8	9.3	9.0			
Cost of funds (%)	3.9	4.9	5.3	5.0	4.6			

Source: Company, Emkay Research

Valuations and key Ratios Y/E Mar FY23 FY24 FY25E FY26E FY27E P/E (x) 13.0 11.5 11.1 10.3 9.0 P/B (x) 2.3 1.9 1.6 1.4 1.2 P/ABV (x) 1.2 2.3 1.9 1.6 1.4 P/PPOP (x) 9.8 8.6 7.6 7.0 6.2 Dividend yield (%) 0.1 0.1 0.1 0.2 0.2 Dupont-RoE split (%) NII/avg assets 3.4 3.6 3.6 3.5 3.5 Other income 1.3 1.6 1.6 1.8 1.8 1.5 1.7 Fee income 1.3 1.5 1.6 2.2 2.5 2.4 2.5 Opex 2.5 PPOP 2.6 2.7 2.8 2.8 2.8 Core PPOP 2.6 2.5 2.6 2.6 2.7 0.3 0.5 Provisions 0.2 0.5 0.5 Tax expense 0.6 0.6 0.5 0.6 0.6 1.7 RoA (%) 0.8 1.8 1.7 1.7 Leverage ratio (x) 10.4 10.1 9.2 8.5 8.2 RoE (%) 8.0 18.0 15.8 14.6 14.4 **Quarterly data** Rs mn, Y/E Mar Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 NII 134,482 136,059 125,322 130,890 134,832 NIM(%) 4.1 3.9 4.0 4.1 4.0 PPOP 91,412 105,357 101,062 107,125 105,339 ΡΑΤ 60.711 69,176 63,038 71.297 60,346 EPS (Rs) 19.71 23.15 19.59 22.46 20.47

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
18-Oct-24	1,197	1,400	Buy	Anand Dama
25-Jul-24	1,176	1,400	Buy	Anand Dama
25-Apr-24	1,127	1,400	Buy	Anand Dama
24-Jan-24	1,059	1,350	Buy	Anand Dama
30-Nov-23	1,074	1,300	Buy	Anand Dama
24-Nov-23	1,009	1,300	Buy	Anand Dama
25-Oct-23	955	1,300	Buy	Anand Dama
26-Jul-23	977	1,260	Buy	Anand Dama
28-Apr-23	860	1,225	Buy	Anand Dama
09-Mar-23	868	1,250	Buy	Anand Dama
02-Mar-23	845	1,250	Buy	Anand Dama
23-Jan-23	933	1,300	Buy	Anand Dama
25-Nov-22	888	1,110	Buy	Anand Dama
21-Oct-22	900	1,110	Buy	Anand Dama
25-Jul-22	727	1,020	Buy	Anand Dama
29-Apr-22	729	1,020	Buy	Anand Dama
31-Mar-22	761	1,020	Buy	Anand Dama
25-Jan-22	752	1,020	Buy	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Source: Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Marke

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of January 17, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of January 17, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 17, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its affiliates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.